Logo image of RNXT

RENOVORX INC (RNXT) Stock Fundamental Analysis

NASDAQ:RNXT - Nasdaq - US75989R1077 - Common Stock - Currency: USD

0.957  -0.02 (-1.83%)

Fundamental Rating

2

RNXT gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RNXT as it has an excellent financial health rating, but there are worries on the profitability. RNXT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year RNXT has reported negative net income.
RNXT had a negative operating cash flow in the past year.
RNXT had negative earnings in each of the past 5 years.
RNXT had a negative operating cash flow in each of the past 5 years.
RNXT Yearly Net Income VS EBIT VS OCF VS FCFRNXT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -2M -4M -6M -8M -10M

1.2 Ratios

The Return On Assets of RNXT (-91.35%) is worse than 72.03% of its industry peers.
The Return On Equity of RNXT (-129.59%) is worse than 61.01% of its industry peers.
Industry RankSector Rank
ROA -91.35%
ROE -129.59%
ROIC N/A
ROA(3y)-290.93%
ROA(5y)-248.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNXT Yearly ROA, ROE, ROICRNXT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 0 -1K -2K -3K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for RNXT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNXT Yearly Profit, Operating, Gross MarginsRNXT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

7

2. Health

2.1 Basic Checks

RNXT has more shares outstanding than it did 1 year ago.
RNXT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RNXT Yearly Shares OutstandingRNXT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M
RNXT Yearly Total Debt VS Total AssetsRNXT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

RNXT has an Altman-Z score of -2.05. This is a bad value and indicates that RNXT is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -2.05, RNXT is in line with its industry, outperforming 54.90% of the companies in the same industry.
RNXT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.05
ROIC/WACCN/A
WACCN/A
RNXT Yearly LT Debt VS Equity VS FCFRNXT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 5M -5M 10M -10M 15M

2.3 Liquidity

A Current Ratio of 5.66 indicates that RNXT has no problem at all paying its short term obligations.
RNXT has a better Current ratio (5.66) than 60.49% of its industry peers.
RNXT has a Quick Ratio of 5.66. This indicates that RNXT is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 5.66, RNXT is doing good in the industry, outperforming 61.01% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 5.66
Quick Ratio 5.66
RNXT Yearly Current Assets VS Current LiabilitesRNXT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

RNXT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.69%, which is quite impressive.
EPS 1Y (TTM)43.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.08%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, RNXT will show a very strong growth in Earnings Per Share. The EPS will grow by 23.63% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y64.78%
EPS Next 2Y28.72%
EPS Next 3Y23.63%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RNXT Yearly Revenue VS EstimatesRNXT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
RNXT Yearly EPS VS EstimatesRNXT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for RNXT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for RNXT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNXT Price Earnings VS Forward Price EarningsRNXT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNXT Per share dataRNXT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as RNXT's earnings are expected to grow with 23.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.72%
EPS Next 3Y23.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for RNXT!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

RENOVORX INC

NASDAQ:RNXT (3/7/2025, 8:00:02 PM)

0.957

-0.02 (-1.83%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13 2024-11-13/amc
Earnings (Next)04-01 2025-04-01/amc
Inst Owners2.85%
Inst Owner Change-46.72%
Ins Owners1.28%
Ins Owner Change0%
Market Cap34.00M
Analysts82.22
Price Target5.61 (486.21%)
Short Float %0.59%
Short Ratio1.37
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.13%
Min EPS beat(2)1.96%
Max EPS beat(2)18.3%
EPS beat(4)3
Avg EPS beat(4)18.18%
Min EPS beat(4)-0.2%
Max EPS beat(4)52.67%
EPS beat(8)5
Avg EPS beat(8)10.1%
EPS beat(12)8
Avg EPS beat(12)6.02%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)4.76%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-6.89%
EPS NY rev (1m)0%
EPS NY rev (3m)4.17%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 4.81
P/tB 4.81
EV/EBITDA N/A
EPS(TTM)-0.58
EYN/A
EPS(NY)-0.38
Fwd EYN/A
FCF(TTM)-0.25
FCFYN/A
OCF(TTM)-0.25
OCFYN/A
SpS0
BVpS0.2
TBVpS0.2
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -91.35%
ROE -129.59%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-290.93%
ROA(5y)-248.18%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.66
Quick Ratio 5.66
Altman-Z -2.05
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.69%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.08%
EPS Next Y64.78%
EPS Next 2Y28.72%
EPS Next 3Y23.63%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y14.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.77%
OCF growth 3YN/A
OCF growth 5YN/A